Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.2963
-0.0096 (-3.14%)
At close: Aug 7, 2026, 4:00 PM EDT
0.3049
+0.0086 (2.90%)
After-hours: Aug 7, 2026, 7:38 PM EDT
Mereo BioPharma Group Stock Forecast
MREO's stock price has decreased by -81.36% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 8 analysts polled by S&P Global, Mereo BioPharma Group stock has a consensus rating of "Buy" and an average price target of $1.98. The average 1-year stock price forecast is 568.24% higher than the current stock price, while the lowest is $1.00 (+237.50%) and the highest is $2.99 (+909.11%).
Price Target: $1.98 (+568.24%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on May 12, 2026.
Analyst Ratings
The average analyst rating for Mereo BioPharma Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Hold Maintains n/a | Hold | Maintains | n/a | n/a | May 12, 2026 |
| Needham | Needham | Buy Maintains $3 | Buy | Maintains | $3 | +912.49% | May 12, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $3 | Buy | Maintains | $3 | +912.49% | May 12, 2026 |
| J.P. Morgan | J.P. Morgan | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Mar 26, 2026 |
| BTIG | BTIG | Buy Maintains $1 | Buy | Maintains | $1 | +237.50% | Mar 20, 2026 |
Financial Forecast
Revenue This Year
9.45M
from 500.00K
Increased by 1,789.71%
Revenue Next Year
22.38M
from 9.45M
Increased by 136.81%
EPS This Year
n/a
EPS Next Year
n/a